Ramucirumab
Cyramza · Anti-VEGFR2 antibody
Hypertension and proteinuria, class effect.
HTNGLOMTMA
ModerateOpen →
BTK inhibitor
Acalabrutinib
Calquence · Acala
A more selective second-generation BTK inhibitor — less hypertension than ibrutinib, with tumor lysis the main renal risk.
MildBTK inhibitor (2nd generation) · approved 2017
CLL/SLLMantle-cell lymphoma
Signature kidney injury
Hypertension
Representative incidence15%
Hypertension occurs but is less frequent than with ibrutinib (~15% vs ~26% in a matched real-world cohort; ELEVATE-RR confirmed lower hypertension and atrial fibrillation head-to-head). One single-center cardio-oncology cohort still found ~49% new/worsened hypertension by sensitive criteria, so it is not negligible. Tumor lysis is the principal route to AKI; direct nephrotoxicity is case-level.
Source: Majrashi et al., Pharmacol Res Perspect 2025 (HTN 15%)
Toxicity fingerprint
Tap a signature to trace where it strikes the nephron.
0%incidence
SeverityMild
ReversibilityVariable
Evidence0 refs
Nephron map
GlomerulusFiltration barrier (podocytes + endothelium)
Vasculature / EndotheliumGlomerular & peritubular capillaries
Hypertension
On-target loss of endothelial nitric oxide from VEGF-pathway blockade — so consistent it marks drug activity.
Mechanism of kidney injury
Greater BTK selectivity reduces the off-target kinase/endothelial effects that drive ibrutinib's hypertension and presumed glomerular endothelial injury, so the hypertension burden is lower. AKI is mainly hemodynamic or from tumor lysis on rapid cytoreduction of bulky CLL/lymphoma (urate/phosphate release with intratubular crystal injury).
Clinical presentation
Generally stable renal function; a blood-pressure rise that is usually milder than ibrutinib; tumor-lysis labs when high-burden disease responds rapidly. Headache (early, self-limited) is a characteristic non-renal effect.
Onset
Tumor lysis early (first cycle); hypertension over weeks–months.
Reversibility
Variable
Anticancer mechanism
More selective covalent BTK inhibitor (binds cysteine-481) with substantially fewer off-target kinase effects than ibrutinib, used in CLL/SLL and mantle-cell lymphoma.
Management
Manage tumor lysis (hydration, rasburicase/allopurinol, electrolyte correction) and hypertension; dose-modify (from 100 mg twice daily) for severe events.
Risk factors
- High tumor burden / bulky disease
- Pre-existing hypertension or CKD
- Volume depletion
- Prior arrhythmia, Black ancestry (for BTKi hypertension)
Prevention
- TLS risk stratification with hydration and urate-lowering therapy
- Blood-pressure monitoring and control
- Monitor renal function during early response
Note · Cardiovascular/renal tolerability is more favorable than ibrutinib, validating ELEVATE-RR in the real world — but hypertension remains a BTKi class effect, so it should still be monitored.
Clinical depth
Renal dose adjustment
No dose adjustment for mild-to-moderate renal impairment (CrCl ≥30 mL/min); severe impairment (CrCl <30) and dialysis are not well studied. <2% renal excretion; hepatic (CYP3A) clearance dominates. Acid-reducing agents alter absorption of the original capsule (a key non-renal interaction).
Dialyzability & ESKD dosing
Not meaningfully dialyzable — highly protein-bound, hepatically cleared small molecule. No post-HD supplemental dosing needed.
Differential diagnosis
As with ibrutinib, separate drug-related effects from CLL-intrinsic kidney disease and tumor lysis. Lower hypertension than ibrutinib helps, but a new BP rise should still be recognized as a likely BTKi class effect rather than dismissed.
Monitoring
- Blood pressure periodically (lower but real hypertension risk)
- Tumor-lysis labs during early cytoreduction of bulky disease
- Serum creatinine and electrolytes
Key trials & series
- Byrd et al., JCO 2021 — ELEVATE-RR, first randomized phase 3 head-to-head vs ibrutinib (lower hypertension and atrial fibrillation)
- Ghia et al., JCO 2020 — ASCEND registrational R/R CLL trial
- Majrashi et al., Pharmacol Res Perspect 2025 — real-world acalabrutinib 15% vs ibrutinib 26.3% hypertension
Clinical pearls
- Acalabrutinib's renal-relevant advantage over ibrutinib is real-world lower hypertension and atrial fibrillation (ELEVATE-RR) — but hypertension is still a class effect.
- The principal route to AKI is tumor lysis during rapid CLL/lymphoma debulking, not direct tubulotoxicity.
- Acid-reducing drugs blunt absorption of the original capsule formulation — an efficacy, not renal, pitfall worth remembering.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Injury signatures
Prerenal / Hemodynamic AKIHypertension
Beyond the kidney
Class-level context for the major non-renal toxicities of btk inhibitors.
Cardiac
Cardiomyopathy, QT, ischemia, myocarditis
- Atrial fibrillation, ventricular arrhythmia
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Bleeding, hypertension
Evidence
7 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkAcalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial.Byrd JC et al. · J Clin Oncol 2021 · PMID 34310172ELEVATE-RR head-to-head: acalabrutinib showed lower hypertension and atrial fibrillation than ibrutinib.PMIDA Comparative Analysis of Cardiovascular Events Associated With Acalabrutinib Versus Ibrutinib in Chronic Lymphocytic Leukemia: Insights From a Global Federated Network.Majrashi A et al. · Pharmacol Res Perspect 2025 · PMID 40341807Real-world cohort: hypertension 15% with acalabrutinib vs 26.3% with ibrutinib.PMIDHypertension and incident cardiovascular events after next-generation BTKi therapy initiation.Chen ST et al. · J Hematol Oncol 2022 · PMID 35836241Acalabrutinib cohort: 48.9% new/worsened hypertension by sensitive criteria; SBP rise predicts cardiac events.PMIDASCEND: Phase III, Randomized Trial of Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.Ghia P et al. · J Clin Oncol 2020 · PMID 32459600ASCEND registrational R/R CLL trial defining efficacy and safety.PMIDHypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.van Dorst DCH et al. · Circ Res 2021 · PMID 33793337Review of BTK-inhibitor–associated hypertension mechanisms and management.PMIDRenal involvement in chronic lymphocytic leukemia.Wanchoo R et al. · Clin Kidney J 2018 · PMID 30288263Onconephrology review of CLL kidney disease and tumor lysis with novel agents.PMIDAcute Kidney Injury Associated with Anticancer Therapies: Small Molecules and Targeted Therapies.Kala J et al. · Kidney360 2024 · PMID 39186376Onconephrology review covering BTK-inhibitor renal effects.
Related agents
Other agents sharing the same signature kidney injury.